Krystal Biotech, Inc. (KRYS) — Fair Value Analysis

Base-case fair value (P50): $342.50 · Current price: $332.27 · Verdict: Fairly Valued

The Verdict on KRYS

KRYSTAL BIOTECH INC (KRYS) is currently assessed as Fairly Valued by our proprietary Monte Carlo simulations, suggesting its market price closely reflects its intrinsic worth. With a median fair value (P50) of $342.50 against its current trading price of $332.27, the analysis indicates an +3.1% upside potential. This narrow deviation between the market price and our simulated fair value underpins the Fairly Valued verdict, signaling that investors are currently paying a price aligned with the company's discounted future cash flows and inherent value drivers. The Monte Carlo approach, evaluating thousands of forward scenarios, converges on this median P50 value, establishing a data-driven benchmark for KRYS's valuation.

How KRYS stacks up against peers

KRYSTAL BIOTECH INC stands out with a strong quality tier, reflecting robust operational and financial health when benchmarked against its industry peers. This fundamental strength is a critical input into our Monte Carlo valuation models, providing a durable foundation for the fair value assessment. Despite the relatively modest +3.1% indicated by the P50 fair value of $342.50 versus the $332.27, KRYS's strong quality tier suggests a lower inherent risk profile in achieving its projected financial outcomes. This superior quality can provide a buffer in various downside scenarios, even as the current price of $332.27 closely tracks the median fair value.

What this means for investors

For investors evaluating KRYSTAL BIOTECH, the Fairly Valued assessment coupled with a strong quality tier implies that KRYS offers a balanced risk-reward profile at its current price of $332.27. While the +3.1% upside to the median fair value of $342.50 is limited, the strong fundamentals suggest resilience. Our Monte Carlo simulations, by considering a broad array of potential future states, support the conclusion that KRYS is priced efficiently. FairCurve users can gain deeper insights by exploring the full distribution of fair values, including more aggressive bull cases and conservative bear scenarios. Sign up for a free FairCurve account to see the full bear/bull distribution and track KRYS's fair value as new fundamentals are released.